<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6612853</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btz331</article-id>
    <article-id pub-id-type="publisher-id">btz331</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Ismb/Eccb 2019 Conference Proceedings</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Studies of Phenotypes and Clinical Applications</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Drug repositioning based on bounded nuclear norm regularization</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Mengyun</given-names>
        </name>
        <xref ref-type="aff" rid="btz331-aff1">1</xref>
        <xref ref-type="aff" rid="btz331-aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Luo</surname>
          <given-names>Huimin</given-names>
        </name>
        <xref ref-type="aff" rid="btz331-aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Yaohang</given-names>
        </name>
        <xref ref-type="aff" rid="btz331-aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1516-0480</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Jianxin</given-names>
        </name>
        <xref ref-type="aff" rid="btz331-aff1">1</xref>
        <xref ref-type="corresp" rid="btz331-cor1"/>
        <!--<email>jxwang@mail.csu.edu.cn</email>-->
      </contrib>
    </contrib-group>
    <aff id="btz331-aff1"><label>1</label>School of Computer Science and Engineering, Central South University, Changsha</aff>
    <aff id="btz331-aff2"><label>2</label>Provincial Key Laboratory of Informational Service for Rural Area of Southwestern Hunan, Shaoyang University, Shaoyang, China</aff>
    <aff id="btz331-aff3"><label>3</label>Department of Computer Science, Old Dominion University, Norfolk, VA, USA</aff>
    <author-notes>
      <corresp id="btz331-cor1">To whom correspondence should be addressed. <email>jxwang@mail.csu.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="ppub">
      <month>7</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2019-07-05">
      <day>05</day>
      <month>7</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>05</day>
      <month>7</month>
      <year>2019</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>35</volume>
    <issue>14</issue>
    <fpage>i455</fpage>
    <lpage>i463</lpage>
    <permissions>
      <copyright-statement>© The Author(s) 2019. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2019</copyright-year>
      <license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btz331.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Computational drug repositioning is a cost-effective strategy to identify novel indications for existing drugs. Drug repositioning is often modeled as a recommendation system problem. Taking advantage of the known drug–disease associations, the objective of the recommendation system is to identify new treatments by filling out the unknown entries in the drug–disease association matrix, which is known as matrix completion. Underpinned by the fact that common molecular pathways contribute to many different diseases, the recommendation system assumes that the underlying latent factors determining drug–disease associations are highly correlated. In other words, the drug–disease matrix to be completed is low-rank. Accordingly, matrix completion algorithms efficiently constructing low-rank drug–disease matrix approximations consistent with known associations can be of immense help in discovering the novel drug–disease associations.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>In this article, we propose to use a bounded nuclear norm regularization (BNNR) method to complete the drug–disease matrix under the low-rank assumption. Instead of strictly fitting the known elements, BNNR is designed to tolerate the noisy drug–drug and disease–disease similarities by incorporating a regularization term to balance the approximation error and the rank properties. Moreover, additional constraints are incorporated into BNNR to ensure that all predicted matrix entry values are within the specific interval. BNNR is carried out on an adjacency matrix of a heterogeneous drug–disease network, which integrates the drug–drug, drug–disease and disease–disease networks. It not only makes full use of available drugs, diseases and their association information, but also is capable of dealing with cold start naturally. Our computational results show that BNNR yields higher drug–disease association prediction accuracy than the current state-of-the-art methods. The most significant gain is in prediction precision measured as the fraction of the positive predictions that are truly positive, which is particularly useful in drug design practice. Cases studies also confirm the accuracy and reliability of BNNR.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>The code of BNNR is freely available at <ext-link ext-link-type="uri" xlink:href="https://github.com/BioinformaticsCSU/BNNR">https://github.com/BioinformaticsCSU/BNNR</ext-link>.</p>
      </sec>
      <sec id="s4">
        <title>Supplementary information</title>
        <p><xref ref-type="supplementary-material" rid="sup1">Supplementary data</xref> are available at <italic>Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <named-content content-type="funder-name">National Natural Science Foundation of China</named-content>
          <named-content content-type="funder-identifier">10.13039/501100001809</named-content>
        </funding-source>
        <award-id>61732009</award-id>
        <award-id>61622213</award-id>
        <award-id>61772552</award-id>
        <award-id>61420106009</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="9"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>The process of new drug discovery is time-consuming and tremendously expensive (<xref rid="btz331-B6" ref-type="bibr">Chong <italic>et al.</italic>, 2007</xref>). It has been showed that the average time of developing a new drug is more than 13.5 years and the cost exceeds $1.8 billion dollars (<xref rid="btz331-B18" ref-type="bibr">Paul <italic>et al.</italic>, 2010</xref>). Discovering new and reliable indications for commercialized drugs allows the pharmaceutical industry and the research community to reduce time and costs, because the existing commercialized drugs have already owned safety, efficacy and toleration data after various tests and clinical trials. The process of identifying new applications for existing drugs is known as drug repositioning. In fact, some successfully repositioned drugs, such as sildenafil, raloxifene and thalidomide, have generated generous revenues for their patent holders or companies. Therefore, drug repositioning is an effective strategy for developing new drugs.</p>
    <p>Computational drug repositioning has attracted increasing attention, since manual investigation is time-consuming. With the development of high throughput technology and continuously updating databases, quite a few computational approaches have been proposed, including network-based analysis, machine learning, text mining and semantic inference approaches. The network-based methods are popular and fundamental for drug repositioning. Based on a network of drugs, diseases and targets (proteins), <xref rid="btz331-B17" ref-type="bibr">Martinez <italic>et al.</italic> (2015)</xref> proposed an approach named DrugNet to predict new use for existing drugs. DrugNet can perform both drug–disease and disease–drug prioritization by propagating information in the heterogeneous network. <xref rid="btz331-B10" ref-type="bibr">Gottlieb <italic>et al.</italic> (2011)</xref> integrated drug similarities and disease similarities to obtain primary features to support a computational approach called PREDICT to identify unknown drug–disease associations. <xref rid="btz331-B24" ref-type="bibr">Wang <italic>et al.</italic> (2013)</xref> constructed a heterogeneous drug–target graph, which contains intra-similarity information and drug–target association information. Based on the guilt-by-association principle, heterogeneous graph based inference (HGBI) algorithm (<xref rid="btz331-B24" ref-type="bibr">Wang <italic>et al.</italic>, 2013</xref>) was proposed to predict new drug–target associations. HGBI is also used for predicting drug–disease associations (<xref rid="btz331-B25" ref-type="bibr">Wang <italic>et al.</italic>, 2014</xref>). <xref rid="btz331-B14" ref-type="bibr">Luo <italic>et al.</italic> (2016)</xref> exploited the available information of drug–disease associations to enhance drug similarity and disease similarity. The MBiRW algorithm, which used some comprehensive similarity measures and Bi-Random Walk (BiRW) algorithm, is implemented on the drug–disease heterogeneous network to predict potential drug–disease associations.</p>
    <p>Matrix factorization and matrix completion techniques have been applied to drug repositioning in recent years. <xref rid="btz331-B7" ref-type="bibr">Dai <italic>et al.</italic> (2015)</xref> incorporated the interaction network of genes and developed a matrix factorization model. Taking advantage of the information in genes network, the association between drug and disease can be predicted and new indications for known drugs can be obtained. <xref rid="btz331-B15" ref-type="bibr">Luo <italic>et al.</italic> (2018)</xref> constructed a heterogeneous network by integrating drug–drug network, disease–disease network and drug–disease association network, and then R<sup>4</sup>SVD (<xref rid="btz331-B13" ref-type="bibr">Li and Yu, 2017</xref>) was employed to efficiently compute the dominant singular values and the corresponding singular vectors of the association matrix. Based on the Singular Value Thresholding (SVT) algorithm (<xref rid="btz331-B3" ref-type="bibr">Cai <italic>et al.</italic>, 2010</xref>), a Drug Repositioning Recommendation System (DRRS) has been proposed to rank the potential associations between drugs and diseases by completing the drug–disease association matrix. In fact, the methods based on random walks are equivalent to certain special cases of those using matrix completions. For example, MBiRW is equivalent to finding the eigenvector with respect to the largest eigenvalue of the association matrix. However, the above matrix completion algorithms are operated in a noiseless setting, assuming that the drug–disease associations are correctly derived and the disease–disease as well as drug–drug similarities are accurately measured. But in reality, drugs and diseases vary in many aspects and it is difficult to construct a single measure to precisely describe the similarity relationship among drugs or diseases. Occasionally, such similarity is misleading. For example, a disease caused by bacteria may have highly similar symptoms as one caused by virus, which should be treated by completely different drugs. Moreover, in the matrix completions algorithms, typically, 1’s in the drug–disease association matrix denote known drug–disease associations while 0’s represent the unknowns. The predicted values are expected to be within the range of [0, 1], indicating the likeliness of the predicted associations. However, the above matrix factorization and completion approaches are unable to avoid the situations that the predicted values fall out of the [0, 1] range, which brings difficulty in biological interpretation.</p>
    <p>In this study, assuming that similar drugs share the similar molecular pathway to treat similar diseases, we consider the prediction of drug–disease association as a noisy matrix completion problem and develop a bounded nuclear norm regularization (BNNR) method to address this problem. First of all, we construct a heterogeneous drug–disease network, which is composed of drug–drug, drug–disease and disease–disease sub-networks. Then, BNNR is implemented to recover the missing entries in the adjacency matrix of this heterogeneous network while tolerating the potential noise in drug–drug and disease–disease similarities calculations. Finally, we evaluate the performance of BNNR on various datasets and compare it with several state-of-the-art methods. Our results show that our approach has superior capability of predicting hidden drug–disease associations. The main contributions of our BNNR model include:
<list list-type="bullet"><list-item><p>BNNR performs noisy matrix completion by incorporating nuclear norm regularization, which effectively addresses overfitting and leads to better improved accuracy as shown in our results;</p></list-item><list-item><p>Our BNNR model incorporates a range constraint, which enforces all predicted matrix entry values within the specific interval;</p></list-item><list-item><p>Our BNNR model is able to deal with noisy data efficiently; and</p></list-item><list-item><p>An efficient iterative scheme is designed to numerically solve the BNNR model.</p></list-item></list></p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <p>In this section, we describe the BNNR model to predict the potential indications for existing drugs, which is organized as follows. First, we describe the datasets used in this study. Then, we depict the construction of the drug–disease heterogeneous network and its adjacency matrix to be completed. Finally, we present the BNNR model, solved by alternating direction method of multipliers (ADMM), to fill out the unknown associations between drugs and diseases. The overall workflow of BNNR is illustrated in <xref ref-type="fig" rid="btz331-F1">Figure 1</xref>.
</p>
    <fig id="btz331-F1" orientation="portrait" position="float">
      <label>Fig. 1.</label>
      <caption>
        <p>The overall workflow of BNNR. (<bold>a</bold>) Drug–drug network and its similarity matrix. (<bold>b</bold>) Disease–disease network and its similarity matrix. (<bold>c</bold>) Drug–disease association network and its association matrix. (<bold>d</bold>) The heterogeneous drug–disease network and its adjacency matrix. (<bold>e</bold>) The model of BNNR</p>
      </caption>
      <graphic xlink:href="btz331f1"/>
    </fig>
    <sec>
      <title>2.1 Datasets</title>
      <p>We use the gold standard dataset to predict new drug indications, which is obtained from (<xref rid="btz331-B10" ref-type="bibr">Gottlieb <italic>et al.</italic>, 2011</xref>) collecting comprehensive associations from multiple data sources. There are 593 drugs, 313 diseases and 1933 validated drug–disease associations. Drugs are collected from the DrugBank database (<xref rid="btz331-B28" ref-type="bibr">Wishart <italic>et al.</italic>, 2006</xref>) and diseases are extracted from the Online Mendelian Inheritance in Man (OMIM) dataset (<xref rid="btz331-B1" ref-type="bibr">Ada <italic>et al.</italic>, 2002</xref>).</p>
      <p>The similarities between drugs are calculated by the Chemical Development Kit (CDK) (<xref rid="btz331-B20" ref-type="bibr">Steinbeck <italic>et al.</italic>, 2003</xref>) according to the chemical structures of all drug compounds in the Canonical Simplified Molecular Input Line-Entry System (SMILES) (<xref rid="btz331-B26" ref-type="bibr">Weininger, 1988</xref>). We firstly download the Canonical SMILES format of all drugs from DrugBank. Then, we utilize CDK to calculate a binary fingerprint for each drug. Finally, the Tanimoto score (<xref rid="btz331-B21" ref-type="bibr">Tanimoto, 1958</xref>) measuring the similarity of pairwise drugs is calculated with respect to their chemical fingerprints, which is in the range of [0, 1].</p>
      <p>Disease–disease similarities are obtained from MimMiner (<xref rid="btz331-B23" ref-type="bibr">Van Driel <italic>et al</italic>., 2006</xref>), which measure the number of appearance of MeSH (medical subject headings vocabulary) terms of two diseases in the medical descriptions obtained from the OMIM database.</p>
    </sec>
    <sec>
      <title>2.2 Construction of the heterogeneous network</title>
      <p>We construct a heterogeneous drug–disease network, which integrates the drug–drug, disease–disease and drug–disease association networks. Let <inline-formula id="IE1"><mml:math id="IM1"><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>}</mml:mo></mml:math></inline-formula> and <inline-formula id="IE2"><mml:math id="IM2"><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>}</mml:mo></mml:math></inline-formula> denote a set of <italic>m</italic> drugs and <italic>n</italic> diseases, respectively. For the drug–drug network, the edge between two drugs is weighted by the pairwise drug similarity value. Similarly, the edge between two diseases is weighted by the pairwise disease similarity value. Then, the drug–disease association network is treated as a bipartite graph <italic>G</italic>(<italic>R</italic>, <italic>D</italic>, <italic>E</italic>), where <inline-formula id="IE3"><mml:math id="IM3"><mml:mi>E</mml:mi><mml:mo>(</mml:mo><mml:mi>G</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>}</mml:mo><mml:mo>⊆</mml:mo><mml:mi>R</mml:mi><mml:mo>×</mml:mo><mml:mi>D</mml:mi></mml:math></inline-formula> contains edges representing known associations between drug <italic>r<sub>i</sub></italic> and disease <italic>d<sub>j</sub></italic>. In this heterogeneous drug–disease network, drug–drug network and disease–disease network are connected by drug–disease associations. <xref ref-type="fig" rid="btz331-F1">Figure 1a–d</xref> illustrates the construction of the heterogeneous network.</p>
      <p>The adjacency matrix of the drug–disease heterogeneous network is then defined as:
<disp-formula id="E1"><mml:math id="M1"><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">RR</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mi mathvariant="italic">DR</mml:mi><mml:mi mathvariant="italic">T</mml:mi></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">DR</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">DD</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:math></disp-formula>
where the sub-matrices <italic>A<sub>RR</sub></italic> and <italic>A<sub>DD</sub></italic> denote the adjacency matrices of drug network and disease network and their weights are set as the pairwise drug and disease similarities, respectively, in range [0, 1]. <italic>A<sub>RR</sub></italic> and <italic>A<sub>DD</sub></italic> are dense which include rich correlation information among drugs and diseases. In contrast, due to the fact that drug–disease associations are rare, <italic>A<sub>DR</sub></italic> is usually extremely sparse, where 1’s denote known drug–disease associations and 0’s correspond to the unknowns. After all, our goal is to fill out the unknown elements in <italic>A<sub>DR</sub></italic> as the predicted scores of potential associations between drugs and diseases.</p>
    </sec>
    <sec>
      <title>2.3 BNNR for predicting drug–disease associations</title>
      <p>Assuming a low-rank structure, the general matrix completion problem (<xref rid="btz331-B19" ref-type="bibr">Ramlatchan <italic>et al.</italic>, 2018</xref>) to fill out the missing entries is formulated as:
<disp-formula id="E2"><mml:math id="M2"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder></mml:mstyle></mml:mrow><mml:mo>⁡</mml:mo><mml:mo> </mml:mo><mml:mrow><mml:mi mathvariant="italic">rank</mml:mi><mml:mo>(</mml:mo><mml:mi>X</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>s</mml:mi><mml:mo>.</mml:mo><mml:mi>t</mml:mi><mml:mo>.</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>X</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
where <inline-formula id="IE4"><mml:math id="IM4"><mml:mi>M</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>m</mml:mi><mml:mo>+</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mo>(</mml:mo><mml:mi>m</mml:mi><mml:mo>+</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> is the given incomplete matrix, <italic>rank</italic>(.) denotes the rank function, Ω is a set containing index pairs (<italic>i</italic>, <italic>j</italic>) of all known entries in <italic>M</italic> and <inline-formula id="IE5"><mml:math id="IM5"><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the projection operator onto Ω.
<disp-formula id="E3"><mml:math id="M3"><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>X</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced open="{" close="" separators="|"><mml:mrow><mml:mtable><mml:mtr columnalign="left"><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo><mml:mo>∈</mml:mo><mml:mo>Ω</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd><mml:mrow><mml:maligngroup/><mml:mo> </mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo><mml:mo>∉</mml:mo><mml:mo>Ω</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>.</mml:mo></mml:mrow></mml:mfenced></mml:math></disp-formula></p>
      <p>Unfortunately, the rank minimization problem is known to be NP-hard. The rank minimization in the above matrix completion model is often relaxed to a nuclear norm minimization problem such that:
<disp-formula id="E4"><label>(1)</label><mml:math id="M4"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder></mml:mstyle></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>s</mml:mi><mml:mo>.</mml:mo><mml:mi>t</mml:mi><mml:mo>.</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
where <inline-formula id="IE6"><mml:math id="IM6"><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula> denotes the nuclear norm of <italic>X</italic>, which is defined as the sum of all singular values of <italic>X</italic>. The nuclear norm minimization model is a convex optimization problem. Many algorithms have been designed to provide numerical solutions for the above model or alternative forms, including the fixed point continuation with approximate SVD (FPCA) (<xref rid="btz331-B16" ref-type="bibr">Ma <italic>et al.</italic>, 2011</xref>), the accelerated proximal gradient algorithm (APG) (<xref rid="btz331-B22" ref-type="bibr">Toh <italic>et al.</italic>, 2010</xref>), the SVT algorithm (<xref rid="btz331-B3" ref-type="bibr">Cai <italic>et al.</italic>, 2010</xref>) and the ADMM (<xref rid="btz331-B2" ref-type="bibr">Boyd <italic>et al.</italic>, 2011</xref>; <xref rid="btz331-B5" ref-type="bibr">Chen <italic>et al.</italic>, 2012</xref>; <xref rid="btz331-B27" ref-type="bibr">Wen <italic>et al.</italic>, 2010</xref>). <xref rid="btz331-B4" ref-type="bibr">Candes <italic>et al.</italic> (2013)</xref> showed that the solution obtained by optimizing the nuclear norm is equivalent to the one by rank minimization under certain conditions, minimizing the nuclear norm.</p>
      <p>For predicting drug–disease associations, the elements in the drug similarity matrix <italic>A<sub>RR</sub></italic> and disease similarity matrix <italic>A<sub>DD</sub></italic> are within the interval of [0, 1]. The elements in the association matrix <italic>A<sub>RD</sub></italic> are either 0 or 1. As a result, the predicted values in the unknown entries are expected to be in the interval of [0, 1], where a predicted value closer to 1 indicates that this is likely to be an indication and vice versa. Nevertheless, in the above matrix completion models (1), the entries in the completed matrix can be any real value in (−<italic>∞</italic>, +<italic>∞</italic>). A predicted value out of the interval [0, 1] is meaningless in the application context. Hence, it is important to add a bound constraint to the matrix completion model to ensure that the uncovered missing elements are within the interval of [0, 1].</p>
      <p>Moreover, since there may be a lot ‘noise’ in the drug and disease data, particularly when measuring the drug–drug and disease–disease similarities, the drug repositioning model should effective tolerate the potential noise. A matrix completion model to tolerate noise is:
<disp-formula id="E5"><mml:math id="M5"><mml:mtable><mml:mtr columnalign="left"><mml:mtd><mml:mrow><mml:maligngroup/><mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder></mml:mstyle></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>s</mml:mi><mml:mo>.</mml:mo><mml:mi>t</mml:mi><mml:mo>.</mml:mo><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>X</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mo>ϵ</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
where ϵ measures the noise level. However, for this model with the inequality constraint, choosing the appropriate parameter is challenging, because the noise level is not explicitly known. Moreover, it is not straightforward to come up with an efficient solver for this model. Therefore, we relax the constraint satisfaction model into a regularization model. Introducing the soft regularization term not only enables tolerance to the unknown noise (<xref rid="btz331-B5" ref-type="bibr">Chen <italic>et al.</italic>, 2012</xref>; <xref rid="btz331-B11" ref-type="bibr">Hu <italic>et al.</italic>, 2013</xref>; <xref rid="btz331-B16" ref-type="bibr">Ma <italic>et al.</italic>, 2011</xref>; <xref rid="btz331-B22" ref-type="bibr">Toh <italic>et al.</italic>, 2010</xref>), but also provides computational convenience.</p>
      <p>Putting all pieces together, we propose a BNNR method, which minimizes the nuclear norm as the regularization term and ensures the recovered matrix elements within a specific interval. The BNNR model is described as follows:
<disp-formula id="E6"><label>(2)</label><mml:math id="M6"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mstyle displaystyle="true"><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder></mml:mstyle><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>X</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>s</mml:mi><mml:mo>.</mml:mo><mml:mi>t</mml:mi><mml:mo>.</mml:mo><mml:mo> </mml:mo><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>X</mml:mi><mml:mo>≤</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
where α is parameter balancing the nuclear norm and the error term. Note that we use <inline-formula id="IE7"><mml:math id="IM7"><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>X</mml:mi><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> to denote <inline-formula id="IE8"><mml:math id="IM8"><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> for all elements in <italic>X</italic> throughout this paper. We derive a simple but effective numerical scheme using ADMM to solve (2).</p>
      <p>Model (2) is solved by an iterative method. Starting from the initial solution<inline-formula id="IE9"><mml:math id="IM9"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>. It is important to notice that the objective function in (2) is convex. By introducing an auxiliary matrix <italic>W</italic>, (2) can be optimized using the ADMM framework in the following equivalent form.
<disp-formula id="E7"><label>(3)</label><mml:math id="M7"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder></mml:mstyle></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mfenced open="‖" close="‖" separators="|"><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mfenced open="‖" close="‖" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:mtd><mml:mtd/></mml:mtr><mml:mtr columnalign="left"><mml:mtd><mml:mi mathvariant="normal">s</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">t</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo> </mml:mo><mml:mi>X</mml:mi><mml:mo>=</mml:mo><mml:mi>W</mml:mi><mml:mo>,</mml:mo><mml:mo> </mml:mo></mml:mtd><mml:mtd><mml:mo> </mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>W</mml:mi><mml:mo>≤</mml:mo><mml:mn>1.</mml:mn></mml:mtd><mml:mtd><mml:mo> </mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
      <p>Accordingly, the augmented Lagrangian function becomes
<disp-formula id="E8"><label>(4)</label><mml:math id="M8"><mml:mtable><mml:mtr><mml:mtd><mml:mi mathvariant="script">L</mml:mi><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>,</mml:mo><mml:mi>X</mml:mi><mml:mo>,</mml:mo><mml:mi>Y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">α</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">β</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:mi mathvariant="italic">Tr</mml:mi><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mo>(</mml:mo><mml:mi>X</mml:mi><mml:mo>-</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi><mml:mo>-</mml:mo><mml:mi>W</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
where <italic>Y</italic> is the Lagrange multiplier and β &gt; 0 is the penalty parameter. At the <italic>k-</italic>th iteration, BNNR requires alternatively computing<inline-formula id="IE10"><mml:math id="IM10"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and<inline-formula id="IE11"><mml:math id="IM11"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>.</p>
      <p><bold>Compute</bold><inline-formula id="IE12"><mml:math id="IM12"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>: We fix <italic>X<sub>k</sub></italic> and <italic>Y<sub>k</sub></italic> to minimize <inline-formula id="IE13"><mml:math id="IM13"><mml:mi mathvariant="script">L</mml:mi><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">α</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">β</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> for<inline-formula id="IE14"><mml:math id="IM14"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>. We hereby take full advantage of the inverse operator to obtain an exact and closed-form solution.
<disp-formula id="E9"><label>(5)</label><mml:math id="M9"><mml:mtable><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi mathvariant="normal">arg</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>W</mml:mi><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:mi mathvariant="script"> </mml:mi><mml:mi mathvariant="script">L</mml:mi><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">α</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">β</mml:mi><mml:mo>)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi mathvariant="normal">arg</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">min</mml:mi><mml:mi mathvariant="normal"> </mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>W</mml:mi><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo> </mml:mo><mml:mo>+</mml:mo><mml:mi mathvariant="italic">Tr</mml:mi><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi>W</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
      <p>Here, <italic>W</italic>* is the optimal solution of <inline-formula id="IE15"><mml:math id="IM15"><mml:mstyle displaystyle="true"><mml:munder><mml:mrow><mml:mi mathvariant="normal">arg</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>W</mml:mi></mml:mrow></mml:munder></mml:mstyle><mml:mo> </mml:mo><mml:mi mathvariant="script">L</mml:mi><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">α</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">β</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>, if and only if
<disp-formula id="E10"><label>(6)</label><mml:math id="M10"><mml:mi mathvariant="normal">α</mml:mi><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi mathvariant="normal">β</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></disp-formula>
holds, where <inline-formula id="IE16"><mml:math id="IM16"><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> denotes the adjoint operator of<inline-formula id="IE17"><mml:math id="IM17"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. Then, a closed-form solution becomes
<disp-formula id="E11"><label>(7)</label><mml:math id="M11"><mml:mtable><mml:mtr><mml:mtd><mml:msup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="script">I</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mi mathvariant="script">I</mml:mi><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">α</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mo>α</mml:mo></mml:mrow><mml:mrow><mml:mo>α</mml:mo><mml:mo>+</mml:mo><mml:mo>β</mml:mo></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mo>Ω</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>β</mml:mo></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo>α</mml:mo></mml:mrow><mml:mrow><mml:mo>β</mml:mo></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mo>Ω</mml:mo></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
where <inline-formula id="IE18"><mml:math id="IM18"><mml:mi mathvariant="script">I</mml:mi></mml:math></inline-formula> is the identity operator. <inline-formula id="IE19"><mml:math id="IM19"><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="script">I</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> denotes the inverse operator of <inline-formula id="IE20"><mml:math id="IM20"><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="script">I</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> and is equal to <inline-formula id="IE21"><mml:math id="IM21"><mml:mi mathvariant="script">I</mml:mi><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">α</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (<xref rid="btz331-B29" ref-type="bibr">Yang and Yuan, 2012</xref>). It’s worth noting that<inline-formula id="IE22"><mml:math id="IM22"><mml:mi mathvariant="normal"> </mml:mi><mml:msubsup><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. Considering the interval <inline-formula id="IE23"><mml:math id="IM23"><mml:mo>[</mml:mo><mml:mn>0,1</mml:mn><mml:mo>]</mml:mo></mml:math></inline-formula> constraint, we limit the range of the elements of <inline-formula id="IE24"><mml:math id="IM24"><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> to [0, 1] such that
<disp-formula id="E12"><label>(8)</label><mml:math id="M12"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">Q</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mn>0,1</mml:mn><mml:mo>]</mml:mo></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
where <inline-formula id="IE25"><mml:math id="IM25"><mml:msub><mml:mrow><mml:mi mathvariant="script">Q</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mn>0,1</mml:mn><mml:mo>]</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula> is the projection operator defined as
<disp-formula id="E13"><mml:math id="M13"><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">Q</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mn>0,1</mml:mn><mml:mo>]</mml:mo></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced open="{" close="" separators="|"><mml:mrow><mml:mtable><mml:mtr columnalign="left"><mml:mtd><mml:mrow><mml:maligngroup/><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:msubsup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msubsup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msubsup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd><mml:mrow><mml:maligngroup/><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:msubsup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced><mml:mo>.</mml:mo></mml:math></disp-formula><bold>Compute</bold><inline-formula id="IE26"><mml:math id="IM26"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>: Alternatively, we fix <inline-formula id="IE27"><mml:math id="IM27"><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <italic>Y<sub>k</sub></italic> to compute<inline-formula id="IE28"><mml:math id="IM28"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>.
<disp-formula id="E14"><label>(9)</label><mml:math id="M14"><mml:mtable><mml:mtr columnalign="left"><mml:mtd><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi mathvariant="normal">argmin</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder><mml:mo> </mml:mo><mml:mi mathvariant="script">L</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>X</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">α</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">β</mml:mi><mml:mo>)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi mathvariant="normal">argmin</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="italic">Tr</mml:mi><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>X</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi mathvariant="normal">argmin</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi><mml:mo>-</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">D</mml:mi></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
      <p>where <inline-formula id="IE29"><mml:math id="IM29"><mml:msub><mml:mrow><mml:mi mathvariant="script">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">τ</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>X</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the singular value shrinkage operator (<xref rid="btz331-B3" ref-type="bibr">Cai <italic>et al.</italic>, 2010</xref>; <xref rid="btz331-B16" ref-type="bibr">Ma <italic>et al.</italic>, 2011</xref>) defined as
<disp-formula id="E15"><mml:math id="M15"><mml:msub><mml:mrow><mml:mi mathvariant="script">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">τ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:munderover><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">σ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mi mathvariant="normal">τ</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">σ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi mathvariant="normal">τ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:msub><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:math></disp-formula>
where σ<sub><italic>i</italic></sub> is the singular values of <italic>X</italic> which is larger than τ, while <italic>u<sub>i</sub></italic> and <italic>v<sub>i</sub></italic> are the left and right singular vectors corresponding to σ<sub><italic>i</italic></sub>, respectively.</p>
      <p><bold>Compute</bold><inline-formula id="IE30"><mml:math id="IM30"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>: Finally, <inline-formula id="IE31"><mml:math id="IM31"><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is calculated as
<disp-formula id="E16"><label>(10)</label><mml:math id="M16"><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">γ</mml:mi><mml:mi mathvariant="normal">β</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi mathvariant="normal">γ</mml:mi><mml:mo>∈</mml:mo><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mfrac><mml:mrow><mml:msqrt><mml:mn>5</mml:mn></mml:msqrt><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula>
where γ is the learning rate, which is set to 1 in this study for simplicity (<xref rid="btz331-B11" ref-type="bibr">Hu <italic>et al.</italic>, 2013</xref>). Putting all pieces together, Algorithm 1 presents an iterative BNNR scheme for solving (2). Based on the assumption that similar diseases tend to be treated by similar drugs, because of the common molecular pathways, there exist certain low-rank structures governing drug–disease associations. Minimizing the nuclear norm of the target matrix, BNNR reveals the low-rank structures and provides a way to recover the missing entries. After supplying the adjacency matrix of the drug–disease heterogeneous network to BNNR, we can obtain an updated drug–disease association matrix<inline-formula id="IE32"><mml:math id="IM32"><mml:mi mathvariant="normal"> </mml:mi><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">DR</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula>, where the unknown entries in <italic>A<sub>DR</sub></italic> are filled up. The entries in <inline-formula id="IE33"><mml:math id="IM33"><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">DR</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> with predicted values (scores) close to 1 indicate the potential drug–disease associations.</p>
      <p>
        <boxed-text id="btz331-BOX1" position="float" orientation="portrait">
          <label>Algorithm 1</label>
          <caption>
            <p>BNNR Algorithm</p>
          </caption>
          <p><bold>Input</bold>: The drug similarity matrix <inline-formula id="IE34"><mml:math id="IM34"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">RR</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>×</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, the disease similarity matrix<inline-formula id="IE35"><mml:math id="IM35"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">DD</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, the drug–disease association matrix<inline-formula id="IE36"><mml:math id="IM36"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">DR</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, parameters α and β.</p>
          <p><bold>Output</bold>: Predicted association matrix<inline-formula id="IE37"><mml:math id="IM37"><mml:mi mathvariant="normal"> </mml:mi><mml:msubsup><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">DR</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula>.</p>
          <p>
            <inline-formula id="IE38">
              <mml:math id="IM38">
                <mml:mi>M</mml:mi>
                <mml:mo>←</mml:mo>
                <mml:mfenced open="[" close="]" separators="|">
                  <mml:mrow>
                    <mml:mtable>
                      <mml:mtr>
                        <mml:mtd>
                          <mml:msub>
                            <mml:mrow>
                              <mml:mi>A</mml:mi>
                            </mml:mrow>
                            <mml:mrow>
                              <mml:mi mathvariant="italic">RR</mml:mi>
                            </mml:mrow>
                          </mml:msub>
                        </mml:mtd>
                        <mml:mtd>
                          <mml:msup>
                            <mml:mrow>
                              <mml:msub>
                                <mml:mrow>
                                  <mml:mi>A</mml:mi>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:mi mathvariant="italic">DR</mml:mi>
                                </mml:mrow>
                              </mml:msub>
                            </mml:mrow>
                            <mml:mrow>
                              <mml:mi>T</mml:mi>
                            </mml:mrow>
                          </mml:msup>
                        </mml:mtd>
                      </mml:mtr>
                      <mml:mtr>
                        <mml:mtd>
                          <mml:msub>
                            <mml:mrow>
                              <mml:mi>A</mml:mi>
                            </mml:mrow>
                            <mml:mrow>
                              <mml:mi mathvariant="italic">DR</mml:mi>
                            </mml:mrow>
                          </mml:msub>
                        </mml:mtd>
                        <mml:mtd>
                          <mml:msub>
                            <mml:mrow>
                              <mml:mi>A</mml:mi>
                            </mml:mrow>
                            <mml:mrow>
                              <mml:mi mathvariant="italic">DD</mml:mi>
                            </mml:mrow>
                          </mml:msub>
                        </mml:mtd>
                      </mml:mtr>
                    </mml:mtable>
                  </mml:mrow>
                </mml:mfenced>
                <mml:mo>;</mml:mo>
                <mml:mo> </mml:mo>
              </mml:math>
            </inline-formula>
          </p>
          <p>initialize <inline-formula id="IE39"><mml:math id="IM39"><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">γ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>;</mml:mo></mml:math></inline-formula> //Ω is a set of indices of all known entries in <italic>M</italic>.</p>
          <p><inline-formula id="IE40"><mml:math id="IM40"><mml:mi>k</mml:mi><mml:mo>←</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula>;</p>
          <p>
            <bold>repeat</bold>
          </p>
          <p>
            <inline-formula id="E17">
              <mml:math id="IM41">
                <mml:mrow>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>W</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi>k</mml:mi>
                      <mml:mo>+</mml:mo>
                      <mml:mn>1</mml:mn>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>←</mml:mo>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi mathvariant="script">Q</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mo>[</mml:mo>
                      <mml:mn>0,1</mml:mn>
                      <mml:mo>]</mml:mo>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>(</mml:mo>
                  <mml:msup>
                    <mml:mrow>
                      <mml:mi>W</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mo>*</mml:mo>
                    </mml:mrow>
                  </mml:msup>
                  <mml:mo>)</mml:mo>
                  <mml:mo>;</mml:mo>
                </mml:mrow>
              </mml:math>
            </inline-formula>
          </p>
          <p>
            <inline-formula>
              <mml:math id="IM42">
                <mml:mrow>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>X</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi>k</mml:mi>
                      <mml:mo>+</mml:mo>
                      <mml:mn>1</mml:mn>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>←</mml:mo>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi mathvariant="script">D</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mfrac>
                        <mml:mrow>
                          <mml:mn>1</mml:mn>
                        </mml:mrow>
                        <mml:mrow>
                          <mml:mi mathvariant="normal">β</mml:mi>
                        </mml:mrow>
                      </mml:mfrac>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>(</mml:mo>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>W</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi>k</mml:mi>
                      <mml:mo>+</mml:mo>
                      <mml:mn>1</mml:mn>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>-</mml:mo>
                  <mml:mfrac>
                    <mml:mrow>
                      <mml:mn>1</mml:mn>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi mathvariant="normal">β</mml:mi>
                    </mml:mrow>
                  </mml:mfrac>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>Y</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi>k</mml:mi>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>)</mml:mo>
                  <mml:mo>;</mml:mo>
                </mml:mrow>
              </mml:math>
            </inline-formula>
          </p>
          <p>
            <inline-formula>
              <mml:math id="IM43">
                <mml:mrow>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>Y</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi>k</mml:mi>
                      <mml:mo>+</mml:mo>
                      <mml:mn>1</mml:mn>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>←</mml:mo>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>Y</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi>k</mml:mi>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>+</mml:mo>
                  <mml:mo>γ</mml:mo>
                  <mml:mo>β</mml:mo>
                  <mml:mo>(</mml:mo>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>X</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi>k</mml:mi>
                      <mml:mo>+</mml:mo>
                      <mml:mn>1</mml:mn>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>-</mml:mo>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>W</mml:mi>
                    </mml:mrow>
                    <mml:mrow>
                      <mml:mi>k</mml:mi>
                      <mml:mo>+</mml:mo>
                      <mml:mn>1</mml:mn>
                    </mml:mrow>
                  </mml:msub>
                  <mml:mo>)</mml:mo>
                  <mml:mo>;</mml:mo>
                </mml:mrow>
              </mml:math>
            </inline-formula>
          </p>
          <p><inline-formula><mml:math id="IM44"><mml:mrow><mml:mi>k</mml:mi><mml:mo>←</mml:mo><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>;</p>
          <p>
            <bold>until convergence</bold>
          </p>
          <p>
            <inline-formula id="E18">
              <mml:math id="IM45">
                <mml:mrow>
                  <mml:mrow>
                    <mml:mo stretchy="true">[</mml:mo>
                    <mml:mrow>
                      <mml:mtable>
                        <mml:mtr columnalign="left">
                          <mml:mtd>
                            <mml:mrow>
                              <mml:msubsup>
                                <mml:mrow>
                                  <mml:mi>A</mml:mi>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:mi>R</mml:mi>
                                  <mml:mi>R</mml:mi>
                                </mml:mrow>
                                <mml:mo>*</mml:mo>
                              </mml:msubsup>
                            </mml:mrow>
                          </mml:mtd>
                          <mml:mtd>
                            <mml:mrow>
                              <mml:msubsup>
                                <mml:mrow>
                                  <mml:mi>A</mml:mi>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:mi>D</mml:mi>
                                  <mml:mi>R</mml:mi>
                                </mml:mrow>
                                <mml:mo>*</mml:mo>
                              </mml:msubsup>
                              <mml:msup>
                                <mml:mrow/>
                                <mml:mi>T</mml:mi>
                              </mml:msup>
                            </mml:mrow>
                          </mml:mtd>
                        </mml:mtr>
                        <mml:mtr columnalign="left">
                          <mml:mtd>
                            <mml:mrow>
                              <mml:msubsup>
                                <mml:mrow>
                                  <mml:mi>A</mml:mi>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:mi>D</mml:mi>
                                  <mml:mi>R</mml:mi>
                                </mml:mrow>
                                <mml:mo>*</mml:mo>
                              </mml:msubsup>
                            </mml:mrow>
                          </mml:mtd>
                          <mml:mtd>
                            <mml:mrow>
                              <mml:msubsup>
                                <mml:mrow>
                                  <mml:mi>A</mml:mi>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:mi>D</mml:mi>
                                  <mml:mi>D</mml:mi>
                                </mml:mrow>
                                <mml:mo>*</mml:mo>
                              </mml:msubsup>
                            </mml:mrow>
                          </mml:mtd>
                        </mml:mtr>
                      </mml:mtable>
                    </mml:mrow>
                    <mml:mo stretchy="true">]</mml:mo>
                  </mml:mrow>
                  <mml:mo>←</mml:mo>
                  <mml:msub>
                    <mml:mrow>
                      <mml:mi>W</mml:mi>
                    </mml:mrow>
                    <mml:mi>k</mml:mi>
                  </mml:msub>
                  <mml:mo>;</mml:mo>
                </mml:mrow>
              </mml:math>
            </inline-formula>
          </p>
          <p>
            <bold>return</bold>
            <inline-formula id="IE41">
              <mml:math id="IM46">
                <mml:msubsup>
                  <mml:mrow>
                    <mml:mi>A</mml:mi>
                  </mml:mrow>
                  <mml:mrow>
                    <mml:mi mathvariant="italic">DR</mml:mi>
                  </mml:mrow>
                  <mml:mrow>
                    <mml:mo>*</mml:mo>
                  </mml:mrow>
                </mml:msubsup>
                <mml:mo>.</mml:mo>
              </mml:math>
            </inline-formula>
          </p>
        </boxed-text>
      </p>
    </sec>
  </sec>
  <sec>
    <title>3 Results and discussion</title>
    <sec>
      <title>3.1 Evaluation metrics</title>
      <p>To evaluate the performance of BNNR, a 10-fold cross-validation is conducted to verify the candidate diseases for given drugs. All known drug–disease associations are randomly divided into 10 exclusive subsets of approximately equal size. Each subset is treated as the testing set in turn, while the remaining nine subsets are used as the training set. The 10-fold cross-validation is repeated 10 times with random subset division and the average accuracy values are showed as the final results.</p>
      <p>After the association matrix of the drug–disease heterogeneous network is completed, the predicted scores of all drug–disease associations are obtained. For each drug, the predicted scores of its associations with the diseases are ranked in descending order. The score of the candidate association exceeding a given threshold is considered as a positive prediction; otherwise, negative. For increasing threshold values, true positive rate (TPR) and false positive rate (FPR) will be calculated to generate the receiver-operating characteristic (ROC) curve. Precision and recall (equivalent to TPR) are obtained to plot the precision–recall (PR) curve (<xref rid="btz331-B9" ref-type="bibr">Davis <italic>et al.</italic>, 2006</xref>). Meanwhile, due to the fact that the top-ranked results are of most interest, the number of correctly identified drug–disease associations using different thresholds will be illustrated. The area under the ROC curve (AUC) and top-ranked results are presented to compare the overall performance of BNNR with a variety of existing methods in this study.</p>
    </sec>
    <sec>
      <title>3.2 Parameter setting</title>
      <p>In BNNR algorithm, there are two parameters needed to be determined, including α and β. For the parameters α and β, we perform cross-validation on the training dataset to determine, which are determined from {0.1, 1, 10, 100}. <xref rid="btz331-T1" ref-type="table">Table 1</xref> reports AUC values calculated by BNNR when α and β are ranging from {0.1, 1, 10, 100} in 10-fold cross-validation, where the best AUC values are displayed in bold. One can find that BNNR achieves the best performance when α = 1 and β = 10.</p>
      <table-wrap id="btz331-T1" orientation="portrait" position="float">
        <label>Table 1.</label>
        <caption>
          <p>The AUC values using different α and β values in 10-fold cross-validation on the gold standard dataset</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="char" char="." span="1"/>
            <col valign="top" align="char" char="." span="1"/>
            <col valign="top" align="char" char="." span="1"/>
            <col valign="top" align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1">α\β</th>
              <th rowspan="1" colspan="1">0.1</th>
              <th rowspan="1" colspan="1">1</th>
              <th rowspan="1" colspan="1">10</th>
              <th rowspan="1" colspan="1">100</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">0.1</td>
              <td rowspan="1" colspan="1">0.757</td>
              <td rowspan="1" colspan="1">0.785</td>
              <td rowspan="1" colspan="1">0.879</td>
              <td rowspan="1" colspan="1">0.888</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1">0.863</td>
              <td rowspan="1" colspan="1">0.921</td>
              <td rowspan="1" colspan="1">
                <bold>0.933</bold>
              </td>
              <td rowspan="1" colspan="1">0.899</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">10</td>
              <td rowspan="1" colspan="1">0.854</td>
              <td rowspan="1" colspan="1">0.921</td>
              <td rowspan="1" colspan="1">0.926</td>
              <td rowspan="1" colspan="1">0.890</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">100</td>
              <td rowspan="1" colspan="1">0.862</td>
              <td rowspan="1" colspan="1">0.919</td>
              <td rowspan="1" colspan="1">0.925</td>
              <td rowspan="1" colspan="1">0.889</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Meanwhile, we terminate the BNNR algorithm when the following stopping criterions are satisfied:
<disp-formula id="E19"><label>(11)</label><mml:math id="M17"><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi mathvariant="italic">tol</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mfrac><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi><mml:mo>{</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:mo>}</mml:mo></mml:mrow></mml:mfrac><mml:mo>≤</mml:mo><mml:mi mathvariant="italic">tol</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo></mml:math></disp-formula>
where<inline-formula id="IE42"><mml:math id="IM47"><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula>, <italic>tol</italic>1 and <italic>tol</italic>2 are the given tolerances, which are set as 2 × 10<sup>−</sup><sup>3</sup> and 10<sup>−</sup><sup>5</sup> in BNNR algorithm, respectively.</p>
    </sec>
    <sec>
      <title>3.3 Compare with other methods</title>
      <p>BNNR is compared with four latest methods for drug repositioning: HGBI (<xref rid="btz331-B24" ref-type="bibr">Wang <italic>et al.</italic>, 2013</xref>), DrugNet (<xref rid="btz331-B17" ref-type="bibr">Martinez <italic>et al.</italic>, 2015</xref>), MBiRW (<xref rid="btz331-B14" ref-type="bibr">Luo <italic>et al.</italic>, 2016</xref>) and DRRS (<xref rid="btz331-B15" ref-type="bibr">Luo <italic>et al.</italic>, 2018</xref>). Based on the guilt-by-association principle and the interpretation of information flow, HGBI is designed for predicting disease-associated drugs. DrugNet is based on propagation flow algorithm, which can perform both drug–disease and disease–drug prioritization. MBiRW and DRRS are our previous works, MBiRW uses comprehensive similarity measures and BiRW algorithm to infer drug–disease association. DRRS constructs a heterogeneous drug–disease network and conducts prediction based on the matrix completion of SVT algorithm to predict potential indications for drugs.</p>
      <p>Although DRRS and BNNR are based on the same heterogeneous drug–disease network, BNNR can exploit more accuracy association information due to better robustness. BNNR has several distinct advantages compared with DRRS: First, BNNR could fit the whole network better. Since the values of similarity matrices computed <italic>in silico</italic> may include noisy information, BNNR has a relaxed penalty function to cope with noisy entries, while DRRS attempts to fit all entries. Second, BNNR has more interpretable predicted values. The bounded constraint ensures that all predicted associations are within [0, 1]. In contrast, the predicted association scores may be negative or &gt;1 in DRRS. Third, the regularization term based on nuclear norm is able to address overfitting effectively. This enables us to design an appropriate stop criterion for BNNR to directly obtain the optimal solution without the need of designating a part of known drug–disease associations as the validation set to identify the optimal rank.</p>
      <p>To ensure a fair comparison, the parameters in the compared approaches are set to the default values according to the authors’ recommendation (HGBI: α = 0.4; MBiRW: α = 0.3, <italic>l</italic> <italic> </italic>= <italic> </italic>2, <italic>r</italic> <italic> </italic>= <italic> </italic>2; DRRS: τ and δ are two adaptive parameters) and cross-validation (DrugNet: α is chosen from {0.1, 0.2, …, 0.9}). The overall results of 10-fold cross-validation for all methods are depicted by ROC curve, PR curve and top-ranked results in <xref ref-type="fig" rid="btz331-F2">Figure 2</xref>. As shown in <xref ref-type="fig" rid="btz331-F2">Figure 2</xref>, the BNNR method outperforms the other methods in terms of AUC values of the ROC curves, precisions and top-ranked indications. Specifically, BNNR reports AUC value of 0.932, while HGBI, DrugNet, MBiRW and DRRS have 0.829, 0.868, 0.917 and 0.930, respectively. The more significant gains are in precision. BNNR obtains prediction precision of 0.440, which is significantly higher than HGBI (0.130), DrugNet (0.192), MBiRW (0.304) and DRRS (0.375). It is important to note that BNNR can successfully rank 44.0% true drug–disease associations at top 1, which is 13.6 and 6.5% higher than MBiRW and DRRS, respectively. One true drug–disease association is treated as a retrieved association when its predicted rank is higher than the specified top rank threshold. These approaches identify different numbers of true drug–disease associations with respect to different rank cutoffs, which are presented in <xref ref-type="fig" rid="btz331-F2">Figure 2c</xref>. For instance, among the 1933 true drug–disease associations, 1333 associations are identified at top 5 by BNNR, while in comparison, only 561, 738, 1044 and 1251 associations are predicted by HGBI, DrugNet, MBiRW and DRRS, respectively. In practice, precision is a more important measure of the drug–disease association prediction performance, because a more precise prediction provides correct indication for existing drugs with higher probability, which can lead to budget and time reduction.
</p>
      <fig id="btz331-F2" orientation="portrait" position="float">
        <label>Fig. 2.</label>
        <caption>
          <p>The performance of all methods in predicting drug–disease association for 10-fold cross-validation. (<bold>a</bold>) ROC curve of prediction results. (<bold>b</bold>) PR curve of predicting candidate diseases for drugs. (<bold>c</bold>) The number of correctly retrieved drug–disease associations for various rank thresholds</p>
        </caption>
        <graphic xlink:href="btz331f2"/>
      </fig>
    </sec>
    <sec>
      <title>3.4 Predicting indications for new drugs</title>
      <p>To assess the capability of BNNR in predicting potential indications for new drugs, we choose these drugs which have only one known drug–disease association to conduct a <italic>de novo</italic> test. For each of these drugs, the known disease association is removed in turn as the test sample and other existing associations are used as training sample.</p>
      <p>For a new drug without any known drug–disease association, BNNR is able to predict its drug–disease associations by taking advantage of the similarity information of the novel drug in adjacency matrix. Also, due to the fact that there is no drug–disease association information for the novel drug, the similarity information is more important than the existing drug–disease association information for the other drugs, which should be given heavier weights. Equivalently, association matrix is multiplied by a weight coefficient 0.7 in this study.</p>
      <p>As shown in <xref ref-type="fig" rid="btz331-F3">Figure 3</xref> for the <italic>de novo</italic> test, BNNR achieves AUC value of 0.830, while HGBI, DrugNet, MBiRW and DRRS have inferior results with 0.746, 0.782, 0.818 and 0.824, respectively. For top-ranked results, BNNR outperforms all methods at top 5, 10 and 50, except for being inferior to DRRS at top 1.
</p>
      <fig id="btz331-F3" orientation="portrait" position="float">
        <label>Fig. 3.</label>
        <caption>
          <p>The performance of all methods in predicting potential diseases for new drugs. (<bold>a</bold>) PR curve of prediction results. (<bold>b</bold>) The number of retrieved drugs for various rank thresholds</p>
        </caption>
        <graphic xlink:href="btz331f3"/>
      </fig>
    </sec>
    <sec>
      <title>3.5 Case studies</title>
      <p>In these case studies, we apply BNNR to predict new uses for already approved drugs in practical applications. In the process of identifying novel drug–disease associations, we treat all known drug–disease associations in the gold standard dataset as the training set and regard the missing drug–disease pairs as the candidate set. After the prediction scores of all candidate pairs are computed by BNNR, we rank the candidate diseases by the predicted scores for each drug.</p>
      <p>In order to confirm whether the predicted diseases are true or not, we choose Levodopa, Doxorubicin, Amantadine and Flecainide as the representative drugs to validate their potential diseases predicted by BNNR and then list the confirmed information of top-5 candidate diseases for them. We confirm the potential diseases associated with the given drug by authoritative public databases, such as DrugBank, CTD (<xref rid="btz331-B8" ref-type="bibr">Davis <italic>et al.</italic>, 2013</xref>) and KEGG (<xref rid="btz331-B12" ref-type="bibr">Kanehisa <italic>et al.</italic>, 2014</xref>). The predicted results and the supporting evidences are summarized in <xref rid="btz331-T2" ref-type="table">Table 2</xref>. For each representative drug, more than three new drug–disease associations on top-5 have been reported in the public databases. It demonstrates the effectiveness of BNNR in predicting novel indications for drugs in practical use.</p>
      <table-wrap id="btz331-T2" orientation="portrait" position="float">
        <label>Table 2.</label>
        <caption>
          <p>The top five candidate diseases for Levodopa, Doxorubicin, Amantadine and Flecainide</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Drugs (DrugBank IDs)</th>
              <th align="left" rowspan="1" colspan="1">Top five candidate diseases (OMIM IDs)</th>
              <th align="left" rowspan="1" colspan="1">Evidences</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="5" colspan="1">Levodopa (DB01235)</td>
              <td rowspan="1" colspan="1">Parkinson disease (168600)</td>
              <td rowspan="1" colspan="1">KEGG/DB/CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Dementia (125320)</td>
              <td rowspan="1" colspan="1">DB/CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Multiple sclerosis (126200)</td>
              <td rowspan="1" colspan="1">CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pheochromocytoma (171300)</td>
              <td rowspan="1" colspan="1">CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hyperplastic myelinopathy (147530)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="5" colspan="1">Doxorubicin (DB00997)</td>
              <td rowspan="1" colspan="1">Small cell cancer of the lung (182280)</td>
              <td rowspan="1" colspan="1">CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Dohle bodies (223350)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Testicular germ cell tumor (273300)</td>
              <td rowspan="1" colspan="1">CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Reticulum cell sarcoma (267730)</td>
              <td rowspan="1" colspan="1">CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Leukemia (109543)</td>
              <td rowspan="1" colspan="1">KEGG/DB/CTD</td>
            </tr>
            <tr>
              <td rowspan="5" colspan="1">Amantadine (DB00915)</td>
              <td rowspan="1" colspan="1">Parkinson disease (168600)</td>
              <td rowspan="1" colspan="1">KEGG/DB/CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Dementia (125320)</td>
              <td rowspan="1" colspan="1">DB/CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Restless legs syndrome (102300)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Alzheimer disease (104300)</td>
              <td rowspan="1" colspan="1">CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Malignant hyperthermia (217150)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="5" colspan="1">Flecainide (DB01195)</td>
              <td rowspan="1" colspan="1">Atrial fibrillation (608583)</td>
              <td rowspan="1" colspan="1">CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Cardiac arrhythmia (115000)</td>
              <td rowspan="1" colspan="1">DB/CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Diastolic hypertension (608622)</td>
              <td rowspan="1" colspan="1">CTD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Nephropathy-hypertension (161900)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hyperplastic myelinopathy (147530)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Furthermore, BNNR identifies other new indications including: Levodopa for hyperplastic myelinopathy; Doxorubicin for dohle bodies; Amantadine for restless legs syndrome and malignant hyperthermia; Flecainide for nephropathy-hypertension and hyperplastic myelinopathy. These predicted associations are not yet reported in current literature, but may have a greater likelihood of existing. There are great opportunities to research and validate these associations for medical researchers and pharmaceutical companies.</p>
    </sec>
    <sec>
      <title>3.6 The effects of bounded constrain and regularization model of BNNR on performance</title>
      <p>In order to evaluate the effectiveness of bounded constraint [0, 1] and regularization model, we compare BNNR with two models in 10-fold cross-validation. The first model is BNNR without bounded constraint [0, 1] (referred to as NNR), while the other one is BNNR without regularization term (referred to as BNN). Specifically, NNR is defined as:
<disp-formula id="E20"><label>(12)</label><mml:math id="M18"><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder></mml:mstyle><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mo>α</mml:mo><mml:mn>2</mml:mn></mml:mfrac><mml:mo>‖</mml:mo><mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mo>Ω</mml:mo></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mo>Ω</mml:mo></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>‖</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
and BNN is defined as:
<disp-formula id="E21"><label>(13)</label><mml:math id="M19"><mml:mrow><mml:mtable><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:munder></mml:mstyle><mml:msub><mml:mrow><mml:mo>‖</mml:mo><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mo>‖</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mi mathvariant="italic">s</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="italic">t</mml:mi><mml:mo>.</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mo>Ω</mml:mo></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">P</mml:mi></mml:mrow><mml:mo>Ω</mml:mo></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>X</mml:mi><mml:mo>≤</mml:mo><mml:mn>1.</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p>
      <p>One can find that incorporating the regularization term leads to more robust prediction results compared to simply minimizing the nuclear norm, where the noise in similarity measures is tolerated. Moreover, constraining the predicted association values within [0, 1] further improves the prediction accuracy. This is shown in the 10-fold cross-validation results illustrated in <xref ref-type="fig" rid="btz331-F4">Figure 4</xref>.
</p>
      <fig id="btz331-F4" orientation="portrait" position="float">
        <label>Fig. 4.</label>
        <caption>
          <p>Performance comparison of BNNR, NNR and BNN in 10-fold cross-validation in terms of AUC values</p>
        </caption>
        <graphic xlink:href="btz331f4"/>
      </fig>
      <p>To further verify the robustness of BNNR, we increasingly add random noises to the drug–drug and disease–disease similarity matrices. The noise entries are drawn independently from <inline-formula id="IE43"><mml:math id="IM48"><mml:mi mathvariant="script">N</mml:mi><mml:mo>(</mml:mo><mml:mn>0,1</mml:mn><mml:mo>/</mml:mo><mml:mn>20</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula> and noise rate is the proportion of the contaminated entries with respect to all components of similarity matrix. We set the noise rate in [0, 0.3] with an increase step size of 0.06. BNNR and BNN are compared in 10-fold cross-validation in terms of AUC values. Without a surprise, as shown in <xref ref-type="fig" rid="btz331-F5">Figure 5</xref>, the AUC values decrease gradually as the noise rate increases in both BNNR and BNN. However, the decrease of BNNR is much slower compared to BNN, indicating that BNNR is able to better tolerate noisy similarity computations. This also explains why BNNR leads to better prediction accuracy when the nuclear norm regularization term is incorporated.
</p>
      <fig id="btz331-F5" orientation="portrait" position="float">
        <label>Fig. 5.</label>
        <caption>
          <p>Performance comparison of BNNR and BNN under different noise rates in terms of AUC values</p>
        </caption>
        <graphic xlink:href="btz331f5"/>
      </fig>
    </sec>
    <sec>
      <title>3.7 Experiments on the other datasets</title>
      <p>In order to illustrate the adaptability of BNNR in different datasets, we perform BNNR on the two other datasets including Cdataset and DNdataset, which are used in our previous work (<xref rid="btz331-B14" ref-type="bibr">Luo <italic>et al.</italic>, 2016</xref>, <xref rid="btz331-B15" ref-type="bibr">2018</xref>). Cdataset (<xref rid="btz331-B14" ref-type="bibr">Luo <italic>et al.</italic>, 2016</xref>) contains 663 drugs collected in DrugBank, 409 diseases obtained in OMIM database and 2352 known drug–disease associations. DNdataset (<xref rid="btz331-B17" ref-type="bibr">Martinez <italic>et al.</italic>, 2015</xref>) includes 1490 drugs registered in DrugBank, 4516 diseases annotated by Disease Ontology (DO) terms and 1008 known drug–disease associations. We evaluate the robustness of our method on these two datasets by performing 10-fold cross-validation and the <italic>de novo</italic> test. The parameters of BNNR for Cdataset and DNdataset are set as Section 3.2. (For Cdataset, α = 1 and β = 10. For DNdataset, α = 1 and β = 1.)</p>
      <p>For Cdataset, as shown in <xref ref-type="fig" rid="btz331-F6">Figure 6</xref>, BNNR obtains AUC value of 0.948 in 10-fold cross-validation, while HGBI, DrugNet, MBiRW and DRRS have 0.858, 0.903, 0.933 and 0.947, respectively. The PR curves illustrate that BNNR obtains the best precision with 0.471, while HGBI, DrugNet, MBiRW and DRRS have 0.168, 0.239, 0.351 and 0.403, respectively. Meanwhile, BNNR outperforms the other methods on top rank results. More specifically, at top-5 rank, 1855 associations out of 2532 are identified by BNNR, while only 796, 1193, 1481 and 1753 associations are predicted by HGBI, DrugNet, MBiRW and DRRS, respectively. In the <italic>de novo</italic> test, PR curve and top rank results are illustrated in <xref ref-type="fig" rid="btz331-F7">Figure 7</xref>. BNNR obtains AUC value of 0.812, while HGBI, DrugNet, MBiRW and DRRS have 0.732, 0.785, 0.804 and 0.819, respectively. DRRS achieves slightly better performance than BNNR. In addition, BNNR outperforms the other methods with respect to different top-ranked thresholds. Specifically, for 177 drug associations, BNNR retrieves 87(49.2%) drugs at top 10 rank, while HGBI, DrugNet, MBiRW and DRRS have 48(27.1%), 61(34.5%), 80(45.2%) and 78(44.0%), respectively.
</p>
      <fig id="btz331-F6" orientation="portrait" position="float">
        <label>Fig. 6.</label>
        <caption>
          <p>The performance of all methods in predicting drug–disease associations for 10-fold cross-validation on Cdataset. (<bold>a</bold>) ROC curve of prediction results. (<bold>b</bold>) PR curve of predicting candidate diseases for drugs. (<bold>c</bold>) The number of correctly retrieved drug–disease associations for various rank threshold</p>
        </caption>
        <graphic xlink:href="btz331f6"/>
      </fig>
      <fig id="btz331-F7" orientation="portrait" position="float">
        <label>Fig. 7.</label>
        <caption>
          <p>The performance of all methods in predicting potential diseases for new drugs on Cdataset. (<bold>a</bold>) PR curve of prediction results. (<bold>b</bold>) The number of retrieved drugs for various rank thresholds</p>
        </caption>
        <graphic xlink:href="btz331f7"/>
      </fig>
      <p>For DNdataset, as shown in <xref ref-type="fig" rid="btz331-F8">Figure 8</xref>, BNNR obtains AUC value of 0.955 in 10-fold cross-validation, while HGBI, DrugNet, MBiRW and DRRS have 0.921, 0.950, 0.956 and 0.934, respectively. The PR curves show that BNNR obtains the best precision with 0.347, while HGBI, DrugNet, MBiRW and DRRS have 0.204, 0.150, 0.321 and 0.346, respectively. It is a noteworthy fact that BNNR has better AUC value and precision compared to other methods. Meanwhile, BNNR outperforms the other methods on top rank results from four different thresholds. In <italic>de novo</italic> test, PR curve and top rank results of <italic>de novo</italic> test are illustrated in <xref ref-type="fig" rid="btz331-F9">Figure 9</xref>. BNNR obtains AUC value of 0.956, which is slightly worse than DrugNet and MBiRW, while HGBI and DRRS have 0.928 and 0.946, respectively. BNNR surpasses the other methods on top rank results: for 347 test drug associations, BNNR retrieves 145 drugs at top 1 rank, while HGBI, DrugNet, MBiRW and DRRS have 111, 84, 136 and 134, respectively.
</p>
      <fig id="btz331-F8" orientation="portrait" position="float">
        <label>Fig. 8.</label>
        <caption>
          <p>The performance of all methods in predicting drug–disease association for 10-fold cross-validation on DNdataset. (<bold>a</bold>) ROC curve of prediction results. (<bold>b</bold>) PR curve of predicting candidate diseases for drugs. (<bold>c</bold>) The number of correctly retrieved drug–disease associations for various rank threshold</p>
        </caption>
        <graphic xlink:href="btz331f8"/>
      </fig>
      <fig id="btz331-F9" orientation="portrait" position="float">
        <label>Fig. 9.</label>
        <caption>
          <p>The performance of all methods in predicting potential diseases for new drugs on DNdataset. (<bold>a</bold>) PR curve of prediction results. (<bold>b</bold>) The number of retrieved drugs for various rank thresholds</p>
        </caption>
        <graphic xlink:href="btz331f9"/>
      </fig>
    </sec>
    <sec>
      <title>3.8 Computation time comparisons</title>
      <p>In order to compare the computational efficiency of different methods, we have conducted a 10-fold cross-validation on the gold standard dataset, Cdataset and DNdataset. The running times of these methods were obtained on a Linux server with CPU 2.30 GHz and 128 GB memory, which are shown in <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref>. The average running time of BNNR is more than HGBI and DrugNet but less than MBiRW and DRRS on the gold standard dataset. Although HGBI is much faster than the others, it yields the lowest precision and AUC values. Moreover, compared to DrugNet on a bigger dataset such as DNdataset, BNNR is more computationally efficient.</p>
    </sec>
  </sec>
  <sec>
    <title>4 Conclusions</title>
    <p>This study has developed a novel method named BNNR for drug repositioning. BNNR not only can restrict all predicted matrix entry values within a specific interval, but also exhibit robustness to tolerate potentially noisy similarity calculations. The results of cross-validation and <italic>de novo</italic> experiments have demonstrated that BNNR is an effective prediction approach. Especially, comparing with the existing drug repositioning methods, BNNR yields both the best AUC value and the best precision in most measures. Our case studies have confirmed the reliability of the identified new drug–disease associations. In the future, we plan to integrate drug–target information into the existing heterogeneous networks to further improve the prediction ability of BNNR.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by the National Natural Science Foundation of China under Grant number (61732009, 61622213, 61772552 and 61420106009).</p>
    <p><italic>Conflict of Interest</italic>: none declared.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sup1">
      <label>btz331_Supplementary_Data</label>
      <media xlink:href="btz331_supplementary_data.doc">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btz331-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ada</surname><given-names>H.</given-names></name></person-group><etal>et al</etal> (<year>2002</year>) 
<article-title>Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders</article-title>. <source>Nucleic Acids Res</source>., <volume>30</volume>, <fpage>52</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">11752252</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B2">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>S.</given-names></name></person-group><etal>et al</etal> (<year>2011</year>) <source>Distributed Optimization and Statistical Learning via the Alternating Direction Method of Multipliers</source>. Foundations and Trends in Machine Learning, <bold>3</bold>, 1–122.</mixed-citation>
    </ref>
    <ref id="btz331-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name></person-group><etal>et al</etal> (<year>2010</year>) 
<article-title>A singular value thresholding algorithm for matrix completion</article-title>. <source>SIAM J. Optim</source>., <volume>20</volume>, <fpage>1956</fpage>–<lpage>1982</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Candes</surname><given-names>E.</given-names></name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>Simple bounds for recovering low-complexity models</article-title>. <source>Math. Program</source>., <volume>141</volume>, <fpage>577</fpage>–<lpage>589</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name></person-group><etal>et al</etal> (<year>2012</year>) 
<article-title>Matrix completion via an alternating direction method</article-title>. <source>IMA J. Numer. Anal</source>., <volume>32</volume>, <fpage>227</fpage>–<lpage>245</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>C.</given-names></name></person-group><etal>et al</etal> (<year>2007</year>) 
<article-title>New uses for old drugs</article-title>. <source>Nature</source>, <volume>448</volume>, <fpage>645</fpage>–<lpage>646</lpage>.<pub-id pub-id-type="pmid">17687303</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name></person-group><etal>et al</etal> (<year>2015</year>) 
<article-title>Matrix factorization-based prediction of novel drug indications by integrating genomic space</article-title>. <source>Comput. Math. Methods Med</source>., <volume>2015</volume>, <fpage>275045</fpage>.<pub-id pub-id-type="pmid">26078775</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>A.</given-names></name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>The comparative toxicogenomics database: update 2013</article-title>. <source>Nucleic Acids Res</source>., <volume>41</volume>, <fpage>D1104</fpage>–<lpage>D1114</lpage>.<pub-id pub-id-type="pmid">23093600</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B9">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>J.</given-names></name></person-group><etal>et al</etal> (<year>2006</year>) The relationship between precision–recall and ROC curves. In: ICML ’06: Proceedings of the International Conference on Machine Learning, New York, NY, USA, pp. <fpage>233</fpage>–<lpage>240</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>A.</given-names></name></person-group><etal>et al</etal> (<year>2011</year>) 
<article-title>PREDICT: a method for inferring novel drug indications with application to personalized medicine</article-title>. <source>Mol. Syst. Biol</source>., <volume>7</volume>, <fpage>496.</fpage><pub-id pub-id-type="pmid">21654673</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>Fast and accurate matrix completion via truncated nuclear norm regularization</article-title>. <source>IEEE Trans. Pattern Anal. Mach. Intell</source>., <volume>35</volume>, <fpage>2117</fpage>–<lpage>2130</lpage>.<pub-id pub-id-type="pmid">23868774</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M.</given-names></name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>Data, information, knowledge and principle: back to metabolism in KEGG</article-title>. <source>Nucleic Acids Res</source>., <volume>42</volume>, <fpage>199</fpage>–<lpage>205</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B13">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name></person-group> (<year>2017</year>) A fast implementation of singular value thresholding algorithm using recycling rank revealing randomized singular value decomposition. arXiv, 1704.05528.</mixed-citation>
    </ref>
    <ref id="btz331-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name></person-group><etal>et al</etal> (<year>2016</year>) 
<article-title>Drug repositioning based on comprehensive similarity measures and Bi-random walk algorithm</article-title>. <source>Bioinformatics</source>, <volume>32</volume>, <fpage>2664</fpage>–<lpage>2671</lpage>.<pub-id pub-id-type="pmid">27153662</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name></person-group><etal>et al</etal> (<year>2018</year>) 
<article-title>Computational drug repositioning using low-rank matrix approximation and randomized algorithms</article-title>. <source>Bioinformatics</source>, <volume>34</volume>, <fpage>1904</fpage>–<lpage>1912</lpage>.<pub-id pub-id-type="pmid">29365057</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name></person-group><etal>et al</etal> (<year>2011</year>) 
<article-title>Fixed point and Bregman iterative methods for matrix rank minimization</article-title>. <source>Math. Program</source>., <volume>128</volume>, <fpage>321</fpage>–<lpage>353</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>V.</given-names></name></person-group><etal>et al</etal> (<year>2015</year>) 
<article-title>DrugNet: network-based drug–disease prioritization by integrating heterogeneous data</article-title>. <source>Artif. Intell. Med</source>., <volume>63</volume>, <fpage>41</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">25704113</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name></person-group><etal>et al</etal> (<year>2010</year>) 
<article-title>How to improve R&amp;D productivity: the pharmaceutical industry’s grand challenge</article-title>. <source>Nat. Rev. Drug Discov</source>., <volume>9</volume>, <fpage>203</fpage>–<lpage>214</lpage>.<pub-id pub-id-type="pmid">20168317</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramlatchan</surname><given-names>A.</given-names></name></person-group><etal>et al</etal> (<year>2018</year>) 
<article-title>A survey of matrix completion methods for recommendation systems</article-title>. <source>Big Data Min. Anal</source>., <volume>1</volume>, <fpage>308</fpage>–<lpage>323</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinbeck</surname><given-names>C.</given-names></name></person-group><etal>et al</etal> (<year>2003</year>) 
<article-title>The Chemistry Development Kit (CDK): an open-source java library for chemo-and bioinformatics</article-title>. <source>J. Chem. Inf. Comput. Sci</source>, <volume>34</volume>, <fpage>493</fpage>–<lpage>500</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B21">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Tanimoto</surname><given-names>T.T.</given-names></name></person-group> (<year>1958</year>) An elementary mathematical theory of classification and prediction. Tech. Rep., IBM Corp.</mixed-citation>
    </ref>
    <ref id="btz331-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toh</surname><given-names>K.</given-names></name></person-group><etal>et al</etal> (<year>2010</year>) 
<article-title>An accelerated proximal gradient algorithm for nuclear norm regularized least squares problems</article-title>. <source>Pac. J. Optim</source>., <volume>6</volume>, <fpage>615</fpage>–<lpage>640</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Driel</surname><given-names>M.A.</given-names></name></person-group><etal>et al</etal> (<year>2006</year>) 
<article-title>A text-mining analysis of the human phenome</article-title>. <source>Eur. J. Hum. Genet</source>., <volume>14</volume>, <fpage>535</fpage>–<lpage>542</lpage>.<pub-id pub-id-type="pmid">16493445</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>Drug target predictions based on heterogeneous graph inference</article-title>. <source>Pac. Symp. Biocomput</source>., <volume>18</volume>, <fpage>53</fpage>–<lpage>64</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>Drug repositioning by integrating target information through a heterogeneous network model</article-title>. <source>Bioinformatics</source>, <volume>30</volume>, <fpage>2923</fpage>–<lpage>2930</lpage>.<pub-id pub-id-type="pmid">24974205</pub-id></mixed-citation>
    </ref>
    <ref id="btz331-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weininger</surname><given-names>D.</given-names></name></person-group> (<year>1988</year>) 
<article-title>SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules</article-title>. <source>J. Chem. Inf. Comput. Sci</source>., <volume>28</volume>, <fpage>31</fpage>–<lpage>36</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name></person-group><etal>et al</etal> (<year>2010</year>) 
<article-title>Alternating direction augmented Lagrangian methods for semi-definite programming</article-title>. <source>Math. Program. Comput</source>., <volume>2</volume>, <fpage>203</fpage>–<lpage>230</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.</given-names></name></person-group><etal>et al</etal> (<year>2006</year>) 
<article-title>DrugBank: a comprehensive resource for in silico drug discovery and exploration</article-title>. <source>Nucleic Acids Res</source>., <fpage>668</fpage>–<lpage>672</lpage>.</mixed-citation>
    </ref>
    <ref id="btz331-B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name></person-group> (<year>2012</year>) 
<article-title>Linearized augmented Lagrangian and alternating direction methods for nuclear norm minimization</article-title>. <source>Math. Comput</source>., <volume>82</volume>, <fpage>301</fpage>–<lpage>329</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
